Diffuse pediatric-type high-grade gliomas, H3-wildtype and IDH-wildtype
Diffuse pediatric-type high-grade gliomas, H3-wildtype and IDH-wildtype are high-grade pediatric tumors recently included in the 5th Edition (2021) of the WHO brain tumor classification.
On this page:
Terminology
Diffuse pediatric-type high-grade gliomas H3-wildtype and IDH-wildtype are classified among the "pediatric-type diffuse high-grade gliomas" (WHO grade 4).
Pathology
Subtypes
Three subtypes of diffuse pediatric-type high-grade gliomas H3-wildtype and IDH-wildtype have been identified on the basis of specific molecular alterations 1:
diffuse pediatric-type high-grade glioma RTK2
diffuse pediatric-type high-grade glioma RTK1
diffuse pediatric-type high-grade glioma MYCN
Location
The location depends on subtype 2:
-
diffuse pediatric-type high-grade glioma RTK2:
supratentorial (96%)
infratentorial (4%)
-
diffuse pediatric-type high-grade glioma RTK1:
supratentorial (82%)
infratentorial (18%)
-
diffuse pediatric-type high-grade glioma MYCN:
supratentorial (86%)
infratentorial (14%)
Microscopic appearance
Diffuse pediatric-type high-grade gliomas, H3-wildtype and IDH-wildtype demonstrate glioblastoma-like features with high cellularity, brisk mitotic activity, microvascular proliferation and necrosis. They may also display sometimes an undifferentiated morphology 3,4.
Radiographic features
Diffuse pediatric-type high-grade gliomas, H3-wildtype and IDH-wildtype are similar to other high-grade gliomas.
On MRI, they may appear as lesions with well-defined margins, homogeneous contrast-enhancement and mild perilesional edema 1,3,4.
Treatment and prognosis
Treatment of diffuse pediatric-type high-grade gliomas H3-wildtype and IDH-wildtype consists of gross total or subtotal tumor resection followed by radiotherapy and chemotherapy. They usually have a poor prognosis with a median overall survival of 17.2 months 5. However median overall survival may vary among the different subtypes 2:
diffuse pediatric-type high-grade glioma RTK1 ( 21 months)
diffuse pediatric-type high-grade glioma RTK2 (44 months)
diffuse pediatric-type high-grade glioma MYCN (14 months)